JPWO2022094334A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022094334A5
JPWO2022094334A5 JP2023526226A JP2023526226A JPWO2022094334A5 JP WO2022094334 A5 JPWO2022094334 A5 JP WO2022094334A5 JP 2023526226 A JP2023526226 A JP 2023526226A JP 2023526226 A JP2023526226 A JP 2023526226A JP WO2022094334 A5 JPWO2022094334 A5 JP WO2022094334A5
Authority
JP
Japan
Prior art keywords
antibody
seq
amino acid
acid sequence
nmosd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023526226A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023549075A (ja
JP2023549075A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/057443 external-priority patent/WO2022094334A1/en
Publication of JP2023549075A publication Critical patent/JP2023549075A/ja
Publication of JPWO2022094334A5 publication Critical patent/JPWO2022094334A5/ja
Publication of JP2023549075A5 publication Critical patent/JP2023549075A5/ja
Pending legal-status Critical Current

Links

JP2023526226A 2020-10-29 2021-10-29 自己免疫疾患を治療するための抗cd19抗体の使用 Pending JP2023549075A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063107182P 2020-10-29 2020-10-29
US63/107,182 2020-10-29
US202163143541P 2021-01-29 2021-01-29
US63/143,541 2021-01-29
US202163178286P 2021-04-22 2021-04-22
US63/178,286 2021-04-22
PCT/US2021/057443 WO2022094334A1 (en) 2020-10-29 2021-10-29 Use of an anti-cd19 antibody to treat autoimmune disease

Publications (3)

Publication Number Publication Date
JP2023549075A JP2023549075A (ja) 2023-11-22
JPWO2022094334A5 true JPWO2022094334A5 (https=) 2024-11-07
JP2023549075A5 JP2023549075A5 (https=) 2024-11-07

Family

ID=81384348

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023526226A Pending JP2023549075A (ja) 2020-10-29 2021-10-29 自己免疫疾患を治療するための抗cd19抗体の使用

Country Status (10)

Country Link
US (1) US20230287114A1 (https=)
EP (1) EP4237447A4 (https=)
JP (1) JP2023549075A (https=)
KR (1) KR20230097118A (https=)
AU (1) AU2021368769A1 (https=)
CA (1) CA3197022A1 (https=)
IL (1) IL302294A (https=)
MX (1) MX2023004794A (https=)
TW (1) TW202233676A (https=)
WO (1) WO2022094334A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023534916A (ja) * 2020-06-30 2023-08-15 ビエラ バイオ インコーポレイテッド 視神経脊髄炎スペクトラム障害を治療する方法
WO2025202213A1 (en) 2024-03-26 2025-10-02 Institut National de la Santé et de la Recherche Médicale Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201401465D0 (en) * 2014-01-29 2014-03-12 Roach Arthur H Use of cladribine for treating autoimmune inflammatory disease
MX2021012870A (es) * 2019-04-24 2022-01-18 Viela Bio Inc Uso de un anticuerpo anti cúmulo de diferenciación 19 (cd19) para tratar enfermedades autoinmunitarias.
JP2023534916A (ja) * 2020-06-30 2023-08-15 ビエラ バイオ インコーポレイテッド 視神経脊髄炎スペクトラム障害を治療する方法

Similar Documents

Publication Publication Date Title
Labcharoenwongs et al. A double-masked comparison of 0.1% tacrolimus ointment and 2% cyclosporine eye drops in the treatment of vernal keratoconjunctivitis in children
US8835487B2 (en) Method of treating multiple sclerosis
Jeffery et al. Treatment of Marburg variant multiple sclerosis with mitoxantrone
US12084491B2 (en) Treatment of Parkinson's disease
US20230406928A1 (en) Methods of treating neuromyelitis optica spectrum disorder
Al Dousary Auditory and vestibular manifestations of Vogt–Koyanagi–Harada disease
WO2022090169A1 (en) Method of safe administration of anti-tau antibody
JP2023548005A (ja) 抗トランスサイレチン抗体およびその使用方法
JPWO2022094334A5 (https=)
JPWO2020219743A5 (https=)
Duran Bilateral anterior uveitis after BNT162b2 mRNA vaccine: Case report
Harris et al. Acute demyelinating disorders of the central nervous system
Khadamy et al. Accelerated recovery: the role of oral steroid in the management of herpes zoster ophthalmicus-related ophthalmoplegia
KR101226605B1 (ko) 질병의 치료
WO2022185224A1 (en) Treatment and/or reduction of occurrence of migraine
Kiss Ixoberogene soroparvovec (Ixo-vec) Intravitreal gene therapy for neovascular age-related macular degeneration
Romac et al. Resolution of pseudophakic cystoid macular edema with combination therapy of topical corticosteroids and nonsteroidal anti-inflammatory drugs
TW202317181A (zh) 治療視神經脊髓炎譜系障礙之方法
Wang et al. Phase 1 dose-escalation study of IBI324, a VEGF-A/Ang-2 bispecific antibody, for the treatment of diabetic macular oedema
Mehndiratta et al. Plasmapheresis for chronic inflammatory demyelinating polyradiculoneuropathy
HK40087593A (zh) 治疗视神经脊髓炎谱系障碍的方法
RU2021134020A (ru) Применение антитела к cd19 для лечения аутоиммунного заболевания
Fowler et al. Cranial nerve syndromes
WO2025106642A1 (en) Methods for the treatment of thyroid eye disease
MAHESHWARI et al. Role of Plasma Exchange in Steroid Resistant Neuromyelitis Optica with Loss of Vision.